Cortisone acetate Clinical Trials

Size	Price	Qty
50mg	USD 147

Clinical Trials

Several clinical trials evaluate cortisone acetate and related glucocorticoid formulations across conditions including primary adrenal insufficiency, polymyalgia rheumatica, giant cell arteritis, knee osteoarthritis, obesity, atopic dermatitis, and dementia. Spanning Phase 2, Phase 4, and non-interventional designs, these studies are sponsored by academic research institutions, university hospital networks, and private healthcare entities. Maintaining active recruitment statuses—including currently recruiting and active, not recruiting—these trials evaluate therapeutic efficacy and systemic hormone regulation.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04855630	Recruiting	Alzheimer Disease\|Dementia	University of Miami\|Shipley Foundation\|Dreem	2023-03-01	Not Applicable
NCT05790083	Active not recruiting	Atopic Dermatitis\|Eczema-Prone Skin	Bionorica SE	2023-01-03	Not Applicable
NCT05336968	Recruiting	Osteoarthritis Knee	United Health Services Hospitals Inc.	2022-09-15	Phase 4
NCT05435781	Recruiting	Adrenal Insufficiency\|Polymyalgia Rheumatica\|Giant Cell Arteritis	Ulla Feldt-Rasmussen\|Aarhus University Hospital\|Odense University Hospital\|Rigshospitalet Denmark	2022-06-07	Phase 4
NCT05237440	Recruiting	Obesity	University Hospital Limoges	2022-04-13	Not Applicable
NCT05222152	Active not recruiting	Primary Adrenal Insufficiency	Diurnal Limited	2021-11-23	Phase 2

(data from https://clinicaltrials.gov, updated on 2024-05-22)

Check the Cortisone acetate product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

As a glucocorticoid steroid, cortisone acetate binds to intracellular glucocorticoid receptors and translocates to the nucleus, where it suppresses pro-inflammatory gene transcription and downregulates inflammatory cytokine signaling. This biochemical inhibition suppresses immune mediator release and reduces tissue inflammation, providing therapeutic efficacy in managing conditions such as primary adrenal insufficiency and osteoarthritis.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).